To the best of our knowledge, this is the first study to examine the correlation of ALS levels with metabolic phenotypes and the effect of the insulin-sensitizer RSG on ALS levels in subjects with type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.